COVID-19 and COVID-19 vaccines-related subacute thyroiditis: analysis of a case series

Year 2022, , 138 - 145, 29.03.2022

Gülçin Türkmen Sarıyıldız , Canan Çiçek , Aykut İlker Arslan , Mehmet Emin Demir

https://doi.org/10.38053/acmj.1061185

Cited By: 1

Abstract

Aim: It has been indicated that COVID-19 is related to many endocrinological abnormalities. The aim of this study is to demonstrate whether there is an impact of COVID-19 and COVID-19 vaccines on development of subacute thyroiditis (SAT).
Material and Method: This retrospective single-center study includes individuals with SAT who were diagnosed between March 2020 and August 2021. Patients were evaluated for a recent Covid-19 history and SARS-CoV-2 vaccination. SAT was diagnosed based on the clinical presentation and laboratory tests; including thyroid function tests, sedimentation rate, C-reactive protein, and thyroid ultrasound. SARS-CoV-2 PCR results of patients with past COVID-19 were obtained from the Ministry of Health electronic patient data system. Type, number, and dates of vaccine doses were recorded for each participant.
Results: A total of 31 patients were included in the study. Six patients (19.4%) were diagnosed with SAT following a COVID-19 vaccination schedule. Four patients with SAT had received two inactive (CoronaVac) + one dose of mRNA vaccines (Pfizer-BioNTech). The other 2 patients had received either two doses of inactive vaccine or two doses of mRNA vaccine. Five patients were diagnosed with SAT after the second dose of the vaccine. The median interval between last vaccination dose and diagnosis of SAT was 25.8 days. In one patient, SAT developed 28 days after the mRNA vaccine. Seven patients (22.6%) were diagnosed with SAT after COVID-19 disease. The median interval from the diagnosis of COVID-19 disease to SAT was 27.3 days. All cases of post-COVID-19 and post-vaccination SAT patients exhibited similar clinical presentation and findings to idiopathic SAT.
Conclusion: Covid-19 itself and Covid-19 vaccines might let a tendency to development of subacute thyroiditis. This study has to be supported by further studies.

Keywords

covid-19, subacute thyroiditis, SARS-CoV2, vaccination

References

• Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nat Med 2020; 26: 1017-32.
• Dong M, Zhang J, Ma X, et al. ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19. Biomed Pharmacother 2020; 131: 110678.
• Caron P. Thyroiditis and SARS-CoV-2 pandemic: a review. Endocrine 2021; 72: 326-31.
• Desailloud R, Hober D. Viruses and thyroiditis: an update. Virol J 2009; 6: 5.
• Bostan H, Unsal IO, Kizilgul M, et al. Two cases of subacute thyroiditis after different types of SARS-CoV-2 vaccination. Arch Endocrinol Metab 2022: 2359-3997000000430.
• Toft J, Larsen S, Toft H. Subacute thyroiditis after hepatitis B vaccination. Endocr J. 1998; 45:135.
• Hsiao JY, Hsin SC,Hsieh MC, Hsia PJ, Shin SJ. Subacute thyroiditis following influenza vaccine (Vaxigrip) in a young female. Kaohsiung J Med Sci 2006; 22: 297-300.
• Plaza-Enriquez L, Khatiwada P, Sanchez-Valenzuela M, Sikha A. A case report of subacute thyroiditis following mRNA COVID-19 vaccine. Case Reports in Endocrinology 2021; 11; 8952048.
• Aemaz Ur Rehman M, Farooq H, Ali MM, Ebaad Ur Rehman M, Dar QA, Hussain A. The association of subacute thyroiditis with COVID-19: a systematic review. SN Compr Clin Med 2021; 1-13.
• Christensen J, O’Callaghan K, Sinclair H, et al. Risk factors, treatment and outcomes of subacute thyroiditis secondary to COVID-19: a systematic review. Intern Med J 2021: 10.1111/imj.15432.
• Campos-Barrera E, Alvarez-Cisneros T, Davalos-Fuentes M. Subacute Thyroiditis associated with COVID-19. Case Rep Endocrinol 2020; 2020: 8891539.
• Bahçecioğlu AB, Karahan ZC, Aydoğan BI, Kalkan IA, Azap A, Erdoğan MF. Subacute thyroiditis during the COVID-19 pandemic: a prospective study. J Endocrinol Invest 2022; 13:1-10.
• Coronavirus vaccinations, Our World in Data, https://ourworldindata.org/covid-vaccinations?country=OWID_WRL, accessed 10 October, 2021.
• Iremli BG, Sendur SN, Unluturk U. Three cases of subacute thyroiditis following SARS-CoV-2 vaccine: postvaccination ASIA syndrome. J Clin Endocrinol Metab 2021; 106: 2600-5.
• Bornemann C, Woyk K, Bouter C. Case report: two cases of subacute thyroiditis following SARS-CoV-2 vaccination. Front Med (Lausanne) 2021; 8: 737142.
• Sözen M, Topaloğlu Ö, Çetinarslan B, et al. COVID-19 mRNA vaccine may trigger subacute thyroiditis. Hum Vaccin Immunother 2021; 10:1-6.
• Coronavirus vaccinations, Our World in Data, https://ourworldindata.org/covid-vaccinations?country=OWID_WRL, accessed 19 September, 2021.
• Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol 2020; 8: 813-22.
• Kumar B, Gopalakrishnan M, Garg MK, et al. Endocrine dysfunction among patients with COVID-19: A single-center experience from a tertiary hospital in India. Indian J Endocr Metab 2021; 25: 14.
• Brancatella A, Ricci D, Viola N, Sgro D, Santini F, Latrofa F. Subacute thyroiditis after Sars-COV-2 infection. J Clin Endocrinol Metabi 2020; 105: 7.
• Ippolito S, Dentali F, Tanda ML. SARS-CoV-2: a potential trigger for subacute thyroiditis? Insights from a case report. J Endocrinol Invest 2020; 43: 1171-2.
• Brancatella A, Ricci D, Cappellani D, et al. Is subacute thyroiditis an underestimated manifestation of SARS-CoV-2 infection? insights from a case series. J Clin Endocrinol Metab 2020; 105: 10.
• Abreu R, Miguel R, Saieg M. Subacute (De Quervain) thyroiditis during the COVID-19 pandemic. Cancer Cytopathol 2021.
• Sohrabpour S, Heidari F, Karimi E, Ansari R, Tajdini A, Heidari F. Subacute thyroiditis in COVID-19 patients. Eur Thyroid J 2021; 9: 321-3.
• Muller I, Cannavaro D, Dazzi D, et al. SARS-CoV-2-related atypical thyroiditis. Lancet Diabetes Endocrinol 2020; 8: 739-41
• Trimboli P, Camponovo C, Franscella S, et al. Subacute thyroiditis during the COVID-19 pandemic: searching for a clinical association with SARS-CoV-2. Int J Endocrinol 2021; 2021: 5588592.
• Pirola I, Gandossi E, Rotondi M, et al. Incidence of De Quervain’s thyroiditis during the COVID-19 pandemic in an area heavily affected by Sars-CoV-2 infection. Endocrine 2021; 74: 215-8.
• Lamers MM, Beumer J, Van der Vaart J, et al. SARS-CoV-2 productively infects human gut enterocytes. Science 2020; 369: 50-4.
• Lindner D, Fitzek A, Brauninger H, et al. Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases. JAMA Cardiol 2020; 5: 1281-5.
• Puelles VG, Lutgehetmann M, Lindenmeyer MT, et al. Multiorgan and renal tropism of SARS-CoV-2. New Engl J Med 2020; 383: 590-2.
• Abreu R, Miguel R, Saieg M. Subacute (De Quervain) thyroiditis during the COVID-19 pandemic. Cancer Cytopathol 2021.Abreu R, Miguel R, Saieg M. Subacute (De Quervain) thyroiditis during the COVID-19 pandemic. Cancer Cytopathol 2021.
• Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty 2020; 9: 45.
• Ruggeri RM, Campenni A, Deandreis D, et al. SARS-COV-2-related immune-inflammatory thyroid disorders: facts and perspectives. Expert Rev Clin Immunol 2021; 17: 737-59.
• Altay FA, Guz G, Altay M. Subacute thyroiditis following seasonal influenza vaccination. Hum Vaccin Immunother 2016; 12: 1033-4.
• Girgis CM, Russo RR, Benson K. Subacute thyroiditis following the H1N1 vaccine. J Endocrinol Invest 2010; 33:506.
• Oyibo SO. Subacute Thyroiditis After receiving the adenovirus-vectored vaccine for Coronavirus disease (COVID-19). Cureus 2021; 13: e16045.
• Das L, Bhadada SK, Sood A. Post-COVID-vaccine autoimmune/inflammatory syndrome in response to adjuvants (ASIA syndrome) manifesting as subacute thyroiditis. J Endocrinol Invest 2021.
• Desailloud R, Hober D. Viruses and thyroiditis: an update. Virol J 2009; 12: 5.